コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 's ability to remove cholesterol from cells (reverse cholesterol transport).
2 lesteryl ester-rich HDL is a central step in reverse cholesterol transport.
3 l) HDL during the antiatherogenic process of reverse cholesterol transport.
4 e of other macrophage proteins implicated in reverse cholesterol transport.
5 glabrata infection, and possibly to enhance reverse cholesterol transport.
6 s in plasma may have an inhibitory effect on reverse cholesterol transport.
7 ed LCAT activation, a critical early step in reverse cholesterol transport.
8 te transporter G1 are involved in macrophage reverse cholesterol transport.
9 ally useful and novel modality for improving reverse cholesterol transport.
10 lipoproteins that are critically involved in reverse cholesterol transport.
11 ABCG1, which are responsible for initiating reverse cholesterol transport.
12 ceptor agonist markedly increases macrophage reverse cholesterol transport.
13 2) generated by CETP inhibition might impair reverse cholesterol transport.
14 e transporter A1 (ABCA1), a key regulator of reverse cholesterol transport.
15 function of phospholipid transfer protein in reverse cholesterol transport.
16 verexpression to promote macrophage-specific reverse cholesterol transport.
17 rotein, and apoE recycling may be related to reverse cholesterol transport.
18 cation of ABCA1 as playing a pivotal role in reverse cholesterol transport.
19 overexpression promotes macrophage-specific reverse cholesterol transport.
20 ting SR-BI cell surface expression and hence reverse cholesterol transport.
21 ipoprotein regulation and may have a role in reverse cholesterol transport.
22 icle formation, apoA-I integrity, and proper reverse cholesterol transport.
23 kely to amplify the effects of oxysterols on reverse cholesterol transport.
24 ein (HDL)-cholesterol and thereby facilitate reverse cholesterol transport.
25 d function of HDL, as well as the pathway of reverse cholesterol transport.
26 criptional regulation of sequential steps of reverse cholesterol transport.
27 its interactions with SR-BI in facilitating reverse cholesterol transport.
28 ins and appears to play an important role in reverse cholesterol transport.
29 iciency of sterol balancing pathways such as reverse cholesterol transport.
30 and chylomicron particles and is involved in reverse cholesterol transport.
31 , a sialoprotein, plays an important role in reverse cholesterol transport.
32 th HDL-cholesterol level and its function in reverse cholesterol transport.
33 ipid composition will have a large impact on reverse cholesterol transport.
34 to bind to HDL and consequently in defective reverse cholesterol transport.
35 atherogenic states that result from impaired reverse cholesterol transport.
36 consistent with the proposed role of HDL in reverse cholesterol transport.
37 e in high density lipoprotein metabolism and reverse cholesterol transport.
38 properties of HDL are related to its role in reverse cholesterol transport.
39 patic SR-BI reduces HDL levels and increases reverse cholesterol transport.
40 rol from peripheral cells, the first step in reverse cholesterol transport.
41 nd in the liver, where it may participate in reverse cholesterol transport.
42 is consistent with its putative function in reverse cholesterol transport.
43 of HDL phospholipid by HL and, therefore, in reverse cholesterol transport.
44 e-rich lipoproteins and processes related to reverse cholesterol transport.
45 of HDL-cholesterol to the liver and impaired reverse cholesterol transport.
46 proteins and is a key regulated component of reverse cholesterol transport.
47 d appears to be a key regulated component of reverse cholesterol transport.
48 oproteins (HDL) and plays a critical role in reverse cholesterol transport.
49 pidation of HDL and has an important role in reverse cholesterol transport.
50 mpered ABCG1-mediated cholesterol efflux and reverse cholesterol transport.
51 High-density lipoprotein plays a key role in reverse cholesterol transport.
52 acyltransferase is a rate-limiting enzyme in reverse cholesterol transport.
53 HDL-C measurement reflect the efficiency of reverse cholesterol transport.
54 of CETP inhibition on cholesterol efflux and reverse cholesterol transport.
55 mphatics to return to the bloodstream during reverse cholesterol transport.
56 rol from macrophages, which is a key step in reverse cholesterol transport.
57 dies indicated the potential of these NPs in reverse cholesterol transport.
58 either carnitine or choline reduced in vivo reverse cholesterol transport.
59 3 (p < 0.01 for each), suggesting increased reverse cholesterol transport.
60 s, which are key acceptors of cholesterol in reverse cholesterol transport.
61 many physiologic functions of HDL, including reverse cholesterol transport.
62 be a promising avenue to increase macrophage reverse cholesterol transport.
63 in arterial macrophages, a critical step in reverse cholesterol transport.
64 either of which would be expected to impede reverse cholesterol transport.
65 triggers LXRalpha activation and macrophage reverse cholesterol transport.
66 r risk factors such as glycaemic control and reverse cholesterol transport.
67 ty lipoprotein (HDL) that is responsible for reverse cholesterol transport.
68 mitantly promoting ABCA1- and ABCG1-mediated reverse cholesterol transport.
69 oA-I with lipids and ABCA1, two key steps in reverse cholesterol transport.
70 e ability of Nef to suppress ABCA1-dependent reverse cholesterol transport.
71 l wall angiogenesis, and macrophage-mediated reverse cholesterol transport.
72 ression of genes involved in anaplerosis and reverse cholesterol transport.
73 alyzed macrophage inflammatory responses and reverse cholesterol transport, 2 key mediators of athero
74 both hypocholesterolemia and an increase in reverse cholesterol transport, a process involving the t
76 only in the loss of classic atheroprotective reverse cholesterol transport activities of the lipoprot
77 ion correlated with functional impairment in reverse cholesterol transport activity of the isolated l
78 agonists have shown promise as promoters of reverse cholesterol transport and anti-inflammatory agen
79 ogenic protection by mechanisms that include reverse cholesterol transport and antiinflammatory funct
80 ng a potential mechanism leading to impaired reverse cholesterol transport and atherosclerosis in the
81 nti-miR33 oligonucleotide treatment promotes reverse cholesterol transport and atherosclerosis regres
82 DL-C and apoA-I levels, facilitating hepatic reverse cholesterol transport and biliary cholesterol ex
83 clerotic, presumably through acceleration of reverse cholesterol transport and by antioxidant and ant
84 agonists may be effective drugs to increase reverse cholesterol transport and decrease cardiovascula
85 ic role of CETP in facilitating HDL-mediated reverse cholesterol transport and demonstrate that CETP
86 tein mediates its beneficial effects through reverse cholesterol transport and direct anti-inflammato
87 otein of high-density lipoproteins, mediates reverse cholesterol transport and has atheroprotective a
88 rotein cholesterol (HDL-C) by promoting both reverse cholesterol transport and HDL antiinflammatory f
89 atherosclerosis by promoting both macrophage reverse cholesterol transport and HDL antiinflammatory f
90 in A-I with enzymes and proteins involved in reverse cholesterol transport and HDL maturation are med
91 tissue as a potential important regulator of reverse cholesterol transport and high density lipoprote
94 SR-BI in the liver plays a critical role in reverse cholesterol transport and it dramatically impact
95 rscore the critical role of prebeta-1 HDL in reverse cholesterol transport and its use as a marker of
96 nosine A2A receptor activation, MTX promotes reverse cholesterol transport and limits foam cell forma
99 addition, its proposed role in facilitating reverse cholesterol transport and modulating atheroscler
100 ause high-density lipoprotein (HDL) promotes reverse cholesterol transport and other antiatherogenic
101 rotein apoAI prevent atherosclerosis through reverse cholesterol transport and other direct effects.
102 vates RHOA and leads to increased macrophage reverse cholesterol transport and reduced atherosclerosi
103 lso induces an SR-BI-independent increase in reverse cholesterol transport and reduces intestinal cho
104 oparticles, offer dual benefits by enhancing reverse cholesterol transport and reducing HIV replicati
105 advanced atherosclerotic plaques, to promote reverse cholesterol transport and resolution of the athe
106 was accompanied by high levels of macrophage reverse cholesterol transport and slightly reduced plasm
107 rocess for many biological events, including reverse cholesterol transport and sperm capacitation.
108 (HDL) and water is an important component of reverse cholesterol transport and the atheroprotective e
109 ion of dysfunctional HDL leading to impaired reverse cholesterol transport and the development of a p
110 density lipoprotein (sHDL), a key player in reverse cholesterol transport and the most abundant form
111 esterol are considered to indicate efficient reverse cholesterol transport and to protect from athero
112 take, plays a role in murine HDL metabolism, reverse cholesterol transport and whole-body cholesterol
113 via a selective uptake pathway to the liver (reverse cholesterol transport) and steroidogenic tissues
114 metabolism, including chylomicron assembly, reverse cholesterol transport, and appetite regulation.
115 g, lipoprotein uptake by peripheral tissues, reverse cholesterol transport, and bile acid synthesis a
116 zygotes and homozygous individuals, decrease reverse cholesterol transport, and lower glucose levels.
117 1)-mediated cholesterol metabolism, increase reverse cholesterol transport, and provide atheroprotect
118 gh-density lipoprotein (HDL) cholesterol and reverse cholesterol transport are being developed to hal
119 roaches that promote HDL function, including reverse cholesterol transport, are in early-stage clinic
121 lipoproteins (HDL), the primary vehicle for reverse cholesterol transport, are the target of serum o
123 eral tissues (ovary, aortic wall), and (iii) reverse cholesterol transport, as indicated by the signi
124 transfer protein may also be a key player in reverse cholesterol transport, as it interacts with the
125 apoA-I by ABCA1 increases its potential for reverse cholesterol transport based on the following fin
126 Liver X receptors (LXRs) centrally control reverse cholesterol transport, but also negatively modul
127 -density lipoprotein is not only involved in reverse cholesterol transport, but also prevents endothe
128 One mechanism is believed to be promotion of reverse cholesterol transport, but no direct proof of th
130 s an antiatherogenic enzyme that facilitates reverse cholesterol transport by esterifying free choles
131 st that acrolein might interfere with normal reverse cholesterol transport by HDL by modifying specif
132 up IIa secretory phospholipase A2, may alter reverse cholesterol transport by HDL during inflammation
133 These findings indicate that HHcy inhibits reverse cholesterol transport by reducing circulating HD
134 l acyltransferase (LCAT) plays a key role in reverse cholesterol transport by transferring an acyl gr
135 iency increases circulating HDL-C levels and reverse cholesterol transport capacity in mice fed a cho
136 sma HDLs in APOM Tg mice, in vivo macrophage reverse cholesterol transport capacity was similar to th
138 of both TMDs on the role of HDL particles on reverse cholesterol transport (cholesterol efflux capaci
139 of LXRalpha in mice substantially decreased reverse cholesterol transport, cholesterol catabolism, a
140 n and suggest that stimulating HDL-dependent reverse cholesterol transport could be beneficial in the
141 of cholesterol transport through HDL (i.e., reverse cholesterol transport) determine the anti-athero
142 ural changes within HDL particles can impede reverse cholesterol transport, enhance oxidation of LDL,
143 3 (miR33) is a key negative regulator of the reverse cholesterol transport factors, ATP-binding casse
144 cipients, suggesting a major requirement for reverse cholesterol transport for the beneficial effects
145 high-density lipoprotein (HDL) synthesis and reverse cholesterol transport, for posttranscriptional r
147 ory, and HDL-mediated cholesterol efflux and reverse cholesterol transport from macrophages are stimu
150 tors of cholesterol homeostasis by governing reverse cholesterol transport from peripheral tissues, b
151 sidered antiatherogenic because they mediate reverse cholesterol transport from the periphery to the
152 jor protein component of HDL-c that mediates reverse cholesterol transport from tissues to the liver
153 nduction of cellular cholesterol efflux and "reverse cholesterol transport" from peripheral tissues t
157 r trafficking of cholesterol, its effect on "reverse cholesterol transport" has not been explored.
158 ies of intestinal cholesterol absorption and reverse cholesterol transport have encouraged the develo
164 L Working Group discusses HDL metabolism and reverse cholesterol transport, impaired HDL as a marker
165 ut that of nascent HDL and how rHDL improves reverse cholesterol transport in an atheroprotective way
166 vidence implicating epigenetic regulation of reverse cholesterol transport in blood in relation to oc
167 physiological with respect to the process of reverse cholesterol transport in heavy drinkers and alco
168 an antiathersclerosis therapy that enhances reverse cholesterol transport in humans and animal model
170 oliferator-activated receptor-gamma-mediated reverse cholesterol transport in macrophages, which cont
171 and EL on HDL metabolism but not macrophage reverse cholesterol transport in mice and an unexpected
173 inding cassette transporter G1 in macrophage reverse cholesterol transport in vivo remain unclear.
177 erent high-density lipoprotein subspecies in reverse cholesterol transport, inflammation, endothelial
178 strategies have been developed that promote reverse cholesterol transport, inhibit inflammatory even
180 decreasing serum LDL levels or accelerating reverse cholesterol transport, inhibition of LDL oxidati
181 the arterial wall as well as later steps of reverse cholesterol transport involving uptake of HDL ch
185 omotion of macrophage cholesterol efflux and reverse cholesterol transport is thought to be one of th
186 ferase (LCAT), an important enzyme affecting reverse cholesterol transport, is expressed in liver and
187 acteristics of the HDL particle, and through reverse cholesterol transport it promotes an antiatherog
188 ate that by enhancing cholesterol efflux and reverse cholesterol transport, macrophage-specific overe
189 RECENT FINDINGS: The contribution of HDL to reverse cholesterol transport may not be as great as fir
190 to the high-density lipoprotein function of reverse cholesterol transport measured by cholesterol ef
191 he results suggested that PBLs activated the reverse cholesterol transport mechanism to enhance the m
192 er studies have cast doubt on the underlying reverse cholesterol transport mechanism: in mice and hum
194 -kappaB and MAPK pathways, but also enhanced reverse cholesterol transport mediated by ABC transporte
197 uced expression of hepatic genes involved in reverse cholesterol transport, most notably, that for sc
198 ranferase (LCAT) catalyzes the first step of reverse cholesterol transport, namely the esterification
199 with ABCA1 transporters, thereby initiating reverse cholesterol transport or, alternatively, renal c
200 the liver and thus constitutes a pathway of reverse cholesterol transport parallel to that mediated
201 eraction with cell-surface components of the reverse cholesterol transport pathway and antiatherogeni
202 ABCG5/G8; these two proteins function in the reverse cholesterol transport pathway and mediate the ef
203 other pathways of cholesterol efflux in the reverse cholesterol transport pathway and prevents apoA-
204 n development that target other parts of the reverse cholesterol transport pathway and, in addition t
205 load of cholesterol in peripheral cells, the reverse cholesterol transport pathway directs excess cho
207 nificant advance in our understanding of the reverse cholesterol transport pathway occurred in 1999 w
209 tical information that may link ABCG1 to the reverse cholesterol transport pathway or diseases such a
210 x capacity (CEC), which is a key step in the reverse cholesterol transport pathway, is independently
211 ill be the manipulation of components of the reverse cholesterol transport pathway, such as CETP, PLT
212 rol is the last step in the atheroprotective reverse cholesterol transport pathway, to which biliary
217 ein A-I (apoA-I) plays a central role in the reverse cholesterol transport pathway; however, the stru
218 al areas: HDL-cholesterol metabolism and the reverse cholesterol transport pathway; novel therapeutic
220 tion in the expression of genes that promote reverse cholesterol transport (PPAR-gamma, LXR-alpha, an
221 to lipoprotein surfaces is a key step in the reverse cholesterol transport process, as the subsequent
222 n can increase expression of antiatherogenic reverse cholesterol transport proteins and can counterac
224 nderpinnings associated with variant HDL and reverse cholesterol transport provides an exceptional op
225 fractional clearance and macrophage to fecal reverse cholesterol transport rates compared with LDLr(-
228 lipoprotein (HDL), which is responsible for reverse cholesterol transport (RCT) and regulation of th
229 Serum high-density lipoproteins (HDLs) and reverse cholesterol transport (RCT) are important therap
230 s fecal cholesterol excretion and macrophage reverse cholesterol transport (RCT) dependent on activat
231 Product but not precursor apo A1 promoted reverse cholesterol transport (RCT) from human aortic sm
232 erosis in mice, but their roles in mediating reverse cholesterol transport (RCT) from macrophages in
233 inhibit atherosclerosis through promotion of reverse cholesterol transport (RCT) in vivo, but this ha
234 onditions, SR-BI-mediated SLU contributes to reverse cholesterol transport (RCT) independently of ABC
240 28.1-kDa protein is a major mediator of the reverse cholesterol transport (RCT) pathway, a process t
242 er, the role that CETP plays in mediation of reverse cholesterol transport (RCT) remains unclear.
244 ty lipoprotein) particles, the first step of reverse cholesterol transport (RCT), is a promising anti
245 ding cassette A1-dependent (ABCA1-dependent) reverse cholesterol transport (RCT), liver X receptor (L
246 ss B member 1 (Scarb1), which is involved in reverse cholesterol transport (RCT), was lower in conven
247 oth of which participate in the HDL-mediated reverse cholesterol transport (RCT), were among the most
248 High-density lipoprotein (HDL) mediates reverse cholesterol transport (RCT), wherein excess chol
259 les for selective cholesterol uptake/efflux (reverse cholesterol transport, RCT) from peripheral cell
260 y the liver accurately reflects the rate of "reverse cholesterol transport." Receptor dependent HDL c
261 ux from macrophage foam cells, a key step in reverse cholesterol transport, requires trafficking of c
263 d cholesterol to the liver by the process of reverse cholesterol transport, resulting in reduction of
264 crophage foam cells is a method of measuring reverse cholesterol transport specifically from macropha
267 r transfer (CET), the proatherogenic step in reverse-cholesterol transport that results in the enrich
268 lipoproteins (HDL) are important vehicles in reverse cholesterol transport, the cardioprotective mech
270 terol efflux is an early, obligatory step in reverse cholesterol transport, the putative antiatheroge
271 uclear receptors that play a central role in reverse cholesterol transport through up-regulation of A
272 erol efflux to apolipoprotein A1 and HDL and reverse cholesterol transport to plasma, liver, and fece
273 g by SR-BI does not influence SR-BI-mediated reverse cholesterol transport to the liver in mice.
275 rease in circulating HDL levels and enhanced reverse cholesterol transport to the plasma, liver, and
277 sity lipoprotein, plays an important role in reverse cholesterol transport via its activity as an ABC
278 rfering with its synthesis or activating the reverse cholesterol transport via the engagement of live
279 w biomarker that characterizes a key step in reverse cholesterol transport, was inversely associated
280 examined atheroprotective function of HDL is reverse cholesterol transport, whereby HDL removes chole
281 atheroprotective effect through its role in reverse cholesterol transport, which comprises the efflu
282 arley-containing meals appeared to stimulate reverse cholesterol transport, which may contribute to t
283 it promotes formation of functional HDL and reverse cholesterol transport, while inhibiting filtrati